isatuximab, carfilzomib, lenalidomide and dexamethasone (isa-krd) in front-line treatment of hig...
Published 3 years ago • 82 plays • Length 3:51
Download video MP4
Download video MP3
Similar videos
-
3:45
gmmg-concept: isa-krd in front-line treatment of high-risk myeloma
-
5:17
gmmg-concept: isa-krd in front-line treatment of high-risk myeloma
-
11:13
isatuximab, carfilzomib, lenalidomide, and dex (isa-krd) in pts with high-risk newly diagnosed mm
-
2:04
isatuximab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma: the skylark trial
-
4:18
isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (ikema)
-
47:40
isatuximab, carfilzomib, lenalidomide & dexamethasone for treatment of high-risk newly diagnosed mm
-
6:50
carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple mye...
-
4:29
ikema: carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma
-
4:29
isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy for ndmm patients
-
3:17
carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma
-
7:55
weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wkrd-d) combination therapy in ...
-
0:50
the safety and efficacy of isatuximab, bortezomib, lenalidomide, and dexamethasone in ndmm
-
1:48
dr. weisel on interim analysis with isatuximab plus krd in high-risk myeloma
-
7:55
isatuximab plus carfilzomib and dex in patients with rrmm: ikema subgroup analysis
-
5:12
carfilzomib, lenalidomide and dex (krd) after asct results in high rates of mrd negativity
-
3:46
ikema: isatuximab, carfilzomib and dexamethasone in rrmm
-
4:04
weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relaps...
-
1:27
four-year follow-up of gmmg-concept: efficacy of isa-krd in high-risk newly diagnosed myeloma
-
46:42
latest developments in the use of immunotherapy for relapsed or refractory multiple myeloma
Clip.africa.com - Privacy-policy